Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia - Concepedia

Concepedia

Publication | Open Access

Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia

DOI Full Paper Access

32

Citations

14

References

2019

Year

Kendra Sweet, Rami S. Komrokji, Eric Padron, Christopher Cubitt, Joel G. Turner, Junmin Zhou, Alan F. List, David A. Sallman, Jana L. Dawson, Daniel M. Sullivan,

Clinical Cancer Research

Abstract

Selinexor plus 7+3 is a safe regimen for patients with newly diagnosed poor-risk AML and warrants further investigation in a larger clinical trial.

References

	Year	Citations

Page 1